---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-001773"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:04:55.981950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic

## Summary
- Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).
- Cash and investments $205.8M at Dec 31, 2021; sufficient to fund operations into first half 2024.
- CAM (ALG-000184) shows best-in-class HBV DNA/RNA reductions; 12-week studies planned for H2 2022.
- ASO (ALG-020572) Phase 1b in CHB initiated, first cohort enrolled; data expected at a conference in H2 2022.
- Expanded Merck NASH collaboration for second oligonucleotide target; COVID-19 3CL PI candidates more potent than nirmatrelvir.

## SEC filing metadata
- accession: 0001171843-22-001773
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/0001171843-22-001773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/f8k_031022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-001773
- JSON: https://secwatch.observer/filing/0001171843-22-001773.json
- Plain text: https://secwatch.observer/filing/0001171843-22-001773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.